Benzinga's Top Upgrades
December 08, 2015 at 09:01 AM EST
Analysts at Goldman Sachs upgraded Myriad Genetics, Inc. (NASDAQ: MYGN) from Sell to Neutral. The price target for Myriad Genetics ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.